(Q80462054)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

31 December 2019

main subject

1 reference

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Marc Brisson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Nicolas Van de Velde

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Philippe De Wals

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

22 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

5399-5408

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Human papillomavirus and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Chapter 13: Current findings from prophylactic HPV vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

An analytical framework for immunization programs in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Development and duration of human papillomavirus lesions, after initial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Costs of colposcopy services and their impact on the incidence and mortality rate of cervical cancer in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Cost-effectiveness analyses of human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

The estimated direct medical cost of sexually transmitted diseases among American youth, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

The health and economic burden of genital warts in a set of private health plans in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

The health care costs of cervical human papillomavirus--related disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.04.086

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2007.04.086

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17561316%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference